All In Biotech

Drug Trial Radar · NCT03822351

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)

Last checked: Nov 19, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 189 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

189

Actual

Start

Dec 19, 2018

Primary completion

Jul 18, 2023

Study completion Jul 18, 2023

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.

Conditions

  • Stage III Non-small Cell Lung Cancer
  • Unresectable

Interventions

  • Durvalumab + OleclumabDrug

    Durvalumab + Oleclumab

  • DurvalumabDrug

    Durvalumab

  • Durvalumab + MonalizumabDrug

    Durvalumab + Monalizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel AgentsTime frame: ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint

Locations

73 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Anaheim, California

  • Research Site

    Duarte, California

  • Research Site

    Sacramento, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    West Haven, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Orlando, Florida

  • Research Site

    Winter Haven, Florida

  • Research Site

    Wichita, Kansas

  • Research Site

    Lexington, Kentucky

  • Research Site

    Louisville, Kentucky

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Covington, Louisiana

  • Research Site

    Rosedale, Maryland

  • Research Site

    Lincoln, Nebraska

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Portland, Oregon

  • Research Site

    Gettysburg, Pennsylvania

  • Research Site

    Lancaster, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Sioux Falls, South Dakota

  • Research Site

    Germantown, Tennessee

  • Research Site

    Memphis, Tennessee

  • Research Site

    Tyler, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Richmond, Virginia

  • Research Site

    Tacoma, Washington

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Bordeaux, France

  • Research Site

    Brest, France

  • Research Site

    Bron, France

  • Research Site

    Créteil, France

  • Research Site

    La Rochelle, France

  • Research Site

    Lille, France

  • Research Site

    Limoges, France

  • Research Site

    Lyon, France

  • Research Site

    Marseille, France

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.